In the present study, we demonstrated that guideline-directed medical therapy and blocking the renin-angiotensin-aldosterone pathway and adrenergic system in patients with HFrEF due to nonischemic DCM resulted in improved LV function and decreased cardiac chamber. The gene discussed is REN; the disease is familial dilated cardiomyopathy.